Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $13.71.

Several analysts have recently weighed in on the company. TD Cowen reiterated a "buy" rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, January 21st. BTIG Research restated a "buy" rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th.

Humacyte Stock Performance

NASDAQ HUMA traded down $0.03 during trading on Friday, hitting $4.13. The stock had a trading volume of 1,357,808 shares, compared to its average volume of 2,303,894. Humacyte has a one year low of $2.81 and a one year high of $9.97. The stock has a 50 day simple moving average of $4.52 and a 200 day simple moving average of $5.38. The stock has a market capitalization of $519.17 million, a price-to-earnings ratio of -3.07 and a beta of 1.30.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.08). During the same period in the previous year, the company earned ($0.25) earnings per share. On average, sell-side analysts predict that Humacyte will post -1.27 EPS for the current year.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares of the company's stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its stake in shares of Humacyte by 27.0% in the 4th quarter. Commonwealth Equity Services LLC now owns 83,128 shares of the company's stock valued at $420,000 after purchasing an additional 17,665 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new stake in Humacyte in the 4th quarter valued at about $177,000. Swiss National Bank lifted its position in Humacyte by 5.8% in the fourth quarter. Swiss National Bank now owns 172,100 shares of the company's stock valued at $869,000 after buying an additional 9,400 shares during the last quarter. HighTower Advisors LLC purchased a new position in Humacyte during the fourth quarter worth about $66,000. Finally, Endowment Wealth Management Inc. increased its position in shares of Humacyte by 3.6% during the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company's stock valued at $526,000 after acquiring an additional 3,590 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.